Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sevoflurane: are there differences in products?

Max T Baker1

  • 1Department of Anesthesia, University of Iowa, Iowa City, Iowa 52242, USA. max-baker@uiowa.edu

Anesthesia and Analgesia
|May 22, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Seizure prevention by the naturally occurring phenols, carvacrol and thymol in a partial seizure-psychomotor model.

Bioorganic & medicinal chemistry letters·2014
Same author

ortho Substituent effects on the anticonvulsant properties of 4-hydroxy-trifluoroethyl phenols.

Bioorganic & medicinal chemistry letters·2012
Same author

The anticonvulsant effects of propofol and a propofol analog, 2,6-diisopropyl-4-(1-hydroxy-2,2,2-trifluoroethyl)phenol, in a 6 Hz partial seizure model.

Anesthesia and analgesia·2010
Same author

Pharmacokinetic characteristics of bolus-administered mannitol in patients undergoing elective craniotomy.

Journal of clinical pharmacology·2010
Same author

Sevoflurane-Lewis acid stability.

Anesthesia and analgesia·2009
Same author

Propofol: the challenges of formulation.

Anesthesiology·2005
Same journal

Incomplete Recovery of Diaphragmatic Mechanics at a Train-of-Four Ratio of 0.90 to <0.95 Assessed by Dynamic Digital Radiography: A Proof-of-Concept Case Series.

Anesthesia and analgesia·2026
Same journal

Patients' Perspectives and Experiences of Participating in Anesthesia Research: A Qualitative Study.

Anesthesia and analgesia·2026
Same journal

Impact of Epidural-Related Maternal Fever on Neonatal Outcomes: A Single-Center Retrospective Case-Control Study Excluding Confirmed Histological Chorioamnionitis.

Anesthesia and analgesia·2026
Same journal

Patient Beliefs and Experiences of Adhering to Medical Therapies for Cardiovascular Comorbidities, Before Noncardiac Elective Surgery in South Africa: A Mixed-Methods Study.

Anesthesia and analgesia·2026
Same journal

Beyond Administrative Indices: Allostatic Load and Autonomic Dyshomeostasis as Biological Mediators of Intraoperative Cardiac Arrest.

Anesthesia and analgesia·2026
Same journal

In Response.

Anesthesia and analgesia·2026
See all related articles

Two sevoflurane anesthetic products, Ultane and a generic version, differ in manufacturing, water content, and packaging despite FDA therapeutic equivalence. These distinctions impact anesthetic stability and suitability for non-glass containers.

Area of Science:

  • Anesthesiology
  • Pharmaceutical Manufacturing
  • Chemical Engineering

Background:

  • Sevoflurane is a widely used volatile anesthetic.
  • Two main products exist: Ultane and a generic formulation.
  • Both are FDA-rated as therapeutically equivalent.

Purpose of the Study:

  • To compare Ultane and generic sevoflurane.
  • To highlight differences in manufacturing, composition, and packaging.
  • To discuss implications for anesthetic stability and container suitability.

Main Methods:

  • Comparative analysis of manufacturing processes.
  • Review of product specifications regarding water content.
  • Evaluation of container materials (plastic vs. aluminum).

Related Experiment Videos

Main Results:

  • Ultane uses a single-step synthesis; generic sevoflurane uses a three-step process.
  • Ultane has higher water content (>300 ppm) than generic sevoflurane (< or =130 ppm).
  • Ultane is packaged in plastic (PEN) bottles; generic sevoflurane in lacquer-lined aluminum bottles.

Conclusions:

  • Differences in manufacturing and packaging may affect sevoflurane stability.
  • Lewis acid reactions can cause sevoflurane degradation.
  • The suitability of non-glass containers for sevoflurane requires consideration.